Particularly, the careSTARTTM G6PD biosensor is suitable for early identification of intermediate and G-6-PD deficiency in newborns, which is the most effective strategy for the prevention of severe hemolytic anemia and the initiation of corrective treatment in a timely manner. This evidence concerns the gene G6PD and hyperinsulinemic hypoglycemia, familial, 4.